source
- Sanofi nixes Kymab-originated OX40L antibody in atopic dermatitisSanofi has decided to stop working on a drug for eczema it had hoped would be a successor to its immunological megablockbuster Dupixent. The French pharma said that it won’t seek ...Endpoints · 5d ago↗ source
- Opinion: I may be one of the last middle-class medical students who could afford to become a doctorA federal loan program made it possible for Gauri Gurumurthy to pursue medicine. Now that program is changing.STAT · 5d ago↗ source
- Opinion: The U.S. pharmaceutical supply chain problem is not about ChinaThe national security framing of the discussion around pharmaceutical supply chain vulnerabilities is a distraction, writes Pooja Yerramilli.STAT · 5d ago↗ source